awmsg logo



anidulafungin (Ecalta®)


Reference No. 345

Publication date:
11/06/2009


Appraisal information

anidulafungin (Ecalta®) 100 mg powder for concentrate for solution for infusion


Company: Pfizer Ltd
BNF category: Infections
NMG meeting date: 25/03/2009
AWMSG meeting date: 29/04/2009
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0809
Ministerial ratification: 10/06/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Anidulafungin (Ecalta®) is recommended as an option for use within NHS Wales within its licensed indication for the treatment of invasive candidiasis in adult non-neutropenic patients. AWMSG is of the opinion that anidulafungin (Ecalta®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download